Inhibiting TRPM2 has been shown to sensitize melanoma cells to redox imbalance and enhance responses to chemotherapeutic agents, positioning it as a potential metabolic checkpoint in melanoma therapy [74]. Here, TRPM2 is linked to melanoma.